| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d81f79f831e4b8da788ba698be288ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f4d86235703b3e2a1cb10b98722d80d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2018-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fad13418313b7e33939d867fa5c12be3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9359edd26c76f96d8abd626b85866b9 |
| publicationDate |
2020-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020088732-A1 |
| titleOfInvention |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| abstract |
The invention relates to methods for predicting the survival time of patients suffering from pancreatic ductal adenocarcinoma (PDA) and methods for the treatment of PDA. The inventors investigated the role of Pancreatitis Associated Protein (PAP/REG3A) as prognostic marker associated with PDA, evaluated its implication in PDA associated nervous system alterations (perineural invasion (PNI)) and its impact on PDAs' patients survival. Using an exvivo assay, they determined its influence on PNI and correlated it with the prognostic value of PAP/REG3A as a circulating biomarker. They demonstrated that PAP/REG3A enhance cancer cells migration and invasion abilities. By activating JAK/STAT signaling pathways, PAP/REG3A favors PNI, known to be associated with relapse after surgery. They also analyzed the level of PAP/REG3A in serum from healthy donors or patients with PDA from three different cohorts and demonstrate that PAP/REG3A is a biomarker of shorter survival as well as poor surgical outcomes with reduced disease-free survival. Thus, the invention relates to a method for predicting the survival time of a patient suffering from PDA and REG3A inhibitors for use in the treatment of PDA. |
| priorityDate |
2017-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |